Compare, Analyse Panacea Biotech with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs ACTAVIS (US) - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PANACEA BIOTECH   ACTAVIS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-19
ACTAVIS
Dec-18
PANACEA BIOTECH/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs35414,240-   
Low Rs1389,552-   
Sales per share (Unadj.) Rs74.63,493.0-  
Earnings per share (Unadj.) Rs6.7-1,125.1-  
Cash flow per share (Unadj.) Rs15.5368.1-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs57.214,406.9-  
Shares outstanding (eoy) m61.25332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.33.4 96.8%   
Avg P/E ratio x36.8-10.6 -348.2%  
P/CF ratio (eoy) x15.932.3 49.1%  
Price / Book Value ratio x4.30.8 520.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m15,0613,956,551 0.4%   
No. of employees `0002.316.9 13.7%   
Total wages/salary Rs m1,4710-   
Avg. sales/employee Rs Th1,973.668,743.5 2.9%   
Avg. wages/employee Rs Th635.60-   
Avg. net profit/employee Rs Th176.8-22,142.3 -0.8%   
INCOME DATA
Net Sales Rs m4,5671,161,765 0.4%  
Other income Rs m4522,217 0.2%   
Total revenues Rs m4,6121,183,982 0.4%   
Gross profit Rs m2,03030,444 6.7%  
Depreciation Rs m540496,629 0.1%   
Interest Rs m1,04867,040 1.6%   
Profit before tax Rs m486-511,009 -0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0130,328 0.0%   
Tax Rs m77-6,476 -1.2%   
Profit after tax Rs m409-374,205 -0.1%  
Gross profit margin %44.42.6 1,696.0%  
Effective tax rate %15.91.3 1,251.3%   
Net profit margin %9.0-32.2 -27.8%  
BALANCE SHEET DATA
Current assets Rs m2,415476,495 0.5%   
Current liabilities Rs m9,077421,524 2.2%   
Net working cap to sales %-145.94.7 -3,083.3%  
Current ratio x0.31.1 23.5%  
Inventory Days Days6520 332.3%  
Debtors Days Days7166 106.9%  
Net fixed assets Rs m8,333131,505 6.3%   
Share capital Rs m610-   
"Free" reserves Rs m3,4430-   
Net worth Rs m3,5044,791,739 0.1%   
Long term debt Rs m4611,687,345 0.0%   
Total assets Rs m13,7557,490,579 0.2%  
Interest coverage x1.5-6.6 -22.1%   
Debt to equity ratio x0.10.4 37.4%  
Sales to assets ratio x0.30.2 214.1%   
Return on assets %10.6-4.1 -258.4%  
Return on equity %11.7-7.8 -149.5%  
Return on capital %38.7-4.8 -799.4%  
Exports to sales %20.90-   
Imports to sales %8.10-   
Net fx Rs m7360-   
CASH FLOW
From Operations Rs m1,049415,055 0.3%  
From Investments Rs m-54228,019 -0.0%  
From Financial Activity Rs m-1,011-712,359 0.1%  
Net Cashflow Rs m-20-68,939 0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 73.59 Rs / USD

Compare PANACEA BIOTECH With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare PANACEA BIOTECH With: ELDER PHARMA  AUROBINDO PHARMA  VENUS REMEDIES  FRESENIUS KABI ONCO.  SANOFI INDIA  



Today's Market

TRAI Data for February, Siemens March Quarter Performance, and Buzzing Stocks Today(Pre-Open)

Indian share markets witnessed selling pressure on Wednesday and ended lower.

Related Views On News

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

Why Did Alembic Pharma Shares Fall Today? (Views On News)

May 5, 2021

Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.

More Views on News

Most Popular

Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

My Secret to Find Breakthrough Stocks (Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

The Worst Sector in the Market (Fast Profits Daily)

May 11, 2021

The worst sector in the stock market according to the charts.

The Key to Profit from India's EV Revolution (Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

FREE Event: Discover Your First Stock for a Potential Rs 7 Crore in Long-term Wealth
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

PANACEA BIOTECH SHARE PRICE


May 12, 2021 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

FEATURED VIDEOS

Top Pick for Next Decade

The 'Big' Money is in this 'Small' Detail

Stability, Quality or Green Stocks for 2021?

Market Crash: Picture Abhi Baaki Hai?

More Featured Videos

MARKET STATS